Literature DB >> 16000601

Limitations of screening for lung cancer with low-dose spiral computed tomography.

James R Jett1.   

Abstract

Past lung cancer screening trials in the United States with chest X-ray and sputum cytology were not able to show any decrease in lung cancer mortality; however, these trials are over 20 years old. Recent follow-up of the Mayo Lung Project showed a better survival from lung cancer in the screened arm, but no difference in overall mortality, suggesting an overdiagnosis of nonfatal cancers. Recent reports of low radiation dose spiral computed tomography (CT) chest screening for lung cancer have shown that CT screening detects cancers at a smaller size than chest X-rays. To date, there have been no randomized trials of CT versus observation or chest radiographs for screening purposes. All data available thus far on CT screening are from phase II proof-of-principle trials. The major limitations of CT screening, discussed here, include (a) a high rate of nodule detection: over 50% of participants will have at least one noncalcified nodule; (b) resulting follow-up CT scans, associated with increased costs; (c) cost and morbidity of biopsy or resection of benign noncalcified nodule (20-25% of such procedures in several trials); and (d) a small, but difficult to quantify, risk of cancer associated with multiple follow-up CT scans.

Entities:  

Mesh:

Year:  2005        PMID: 16000601     DOI: 10.1158/1078-0432.CCR-05-9000

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  22 in total

Review 1.  Screening for lung cancer using low-dose spiral CT: 10 years later, state of the art.

Authors:  M Zompatori; M Mascalchi; F Ciccarese; N Sverzellati; U Pastorino
Journal:  Radiol Med       Date:  2012-06-28       Impact factor: 3.469

2.  What do you mean, a spot?: A qualitative analysis of patients' reactions to discussions with their physicians about pulmonary nodules.

Authors:  Renda Soylemez Wiener; Michael K Gould; Steven Woloshin; Lisa M Schwartz; Jack A Clark
Journal:  Chest       Date:  2013-03       Impact factor: 9.410

3.  Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease.

Authors:  Michael K Showe; Anil Vachani; Andrew V Kossenkov; Malik Yousef; Calen Nichols; Elena V Nikonova; Celia Chang; John Kucharczuk; Bao Tran; Elliot Wakeam; Ting An Yie; David Speicher; William N Rom; Steven Albelda; Louise C Showe
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

4.  In vivo three-dimensional imaging of normal tissue and tumors in the rabbit pleural cavity using endoscopic swept source optical coherence tomography with thoracoscopic guidance.

Authors:  Tuqiang Xie; Gangjun Liu; Kelly Kreuter; Sari Mahon; Henri Colt; David Mukai; George M Peavy; Zhongping Chen; Matthew Brenner
Journal:  J Biomed Opt       Date:  2009 Nov-Dec       Impact factor: 3.170

Review 5.  Clinical impact of high-throughput gene expression studies in lung cancer.

Authors:  Jennifer Beane; Avrum Spira; Marc E Lenburg
Journal:  J Thorac Oncol       Date:  2009-01       Impact factor: 15.609

6.  Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.

Authors:  Pierre P Massion; Graham F Healey; Laura J Peek; Lynn Fredericks; Herb F Sewell; Andrea Murray; John F R Robertson
Journal:  J Thorac Oncol       Date:  2016-09-08       Impact factor: 15.609

7.  Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study.

Authors:  Jun Maeda; Masahiko Higashiyama; Akira Imaizumi; Tomio Nakayama; Hiroshi Yamamoto; Takashi Daimon; Minoru Yamakado; Fumio Imamura; Ken Kodama
Journal:  BMC Cancer       Date:  2010-12-22       Impact factor: 4.430

8.  Long-term outcomes of a pilot CT screening for lung cancer.

Authors:  G Veronesi; P Maisonneuve; L Spaggiari; C Rampinelli; G Pelosi; L Preda; F Petrella; A Borri; M Casiraghi; R Bertolotti; N Rotmensz; M Bellomi
Journal:  Ecancermedicalscience       Date:  2010-05-13

Review 9.  Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy.

Authors:  Meleeneh Kazarian; Ite A Laird-Offringa
Journal:  Mol Cancer       Date:  2011-03-30       Impact factor: 27.401

Review 10.  Lung cancer screening update.

Authors:  Massimo Bellomi; Cristiano Rampinelli; Elvio De Fiori; Lorenzo Preda; Giulia Veronesi
Journal:  Cancer Imaging       Date:  2009-10-02       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.